**BMJ Open**

**Vitamin B_{12} deficiency and hyperhomocysteinaemia in outpatients with stroke or transient ischaemic attack: a cohort study at an academic medical centre**

Shamon Ahmed, 1 Chrysi Bogiatzi, Daniel G Hackam, 2, 3, 4 Angela C Rutledge, 5, 6 Luciano A Sposato, 4, 7, 8 Alexander Khaw, 4, 7 Jennifer Mandzia, 4, 7 Mahmoud Reza Azarpazhoo, 4, 7 Vladimir Hachinski, 4, 7 J David Spence 2, 3, 4, 7, 9

**ABSTRACT**

**Objective** We sought to assess the current magnitude of the opportunity for secondary stroke prevention with B vitamins.

**Design** A cohort study.

**Setting** The Urgent TIA (Transient Ischaemic Attack) Clinic at an academic medical centre.

**Main outcome measures** We assessed the prevalence of biochemical vitamin B_{12} deficiency (B_{12} Def, serum B_{12} <156 pmol/L), hyperhomocysteinaemia (HHcy; plasma total homocysteine [tHcy] >14 pmol/L) and metabolic B_{12} deficiency (MetB_{12} Def, serum B_{12} <258 pmol/L and HHcy) between 2002 and 2017, by age group and by stroke subtype.

**Results** Data were available in 4055 patients. B_{12} Def was present in 8.2% of patients overall; it declined from 10.9% of patients referred before 2009 to 5.4% thereafter (p<0.0001). MetB_{12} Def was present in 10.6% of patients, and HHcy was present in 19.1% of patients. Among the patients aged ≥80 years, MetB_{12} Def was present in 18.1% and HHcy in 35%. Among the 3410 patients whose stroke subtype was determined, HHcy was present in 18.4% of patients; 23.3% of large artery atherosclerosis, 18.1% of cardioembolic, 16.3% of small vessel disease, 10.8% of other unusual aetiologies and 13.6% of undetermined subtypes (p<0.0001).

**Conclusions** Despite a decline in our referral area since 2009, B_{12} Def, MetB_{12} Def and HHcy remain common in patients with stroke/TIA. Because these conditions are easily treated and have serious consequences, all patients with stroke/TIA should have their serum B_{12} and tHcy measured.

**INTRODUCTION**

There is a commonly held belief that “Homocysteine is dead.” This apparently has its origins in a widely quoted statement made by Dr Kaare Harald Bønaa in September 2005 at the European Society of Cardiology Congress in Stockholm. Indeed, this very phrase was cited by an official at the National Institute for Health and Care Excellence (NICE) in the UK as the reason that NICE recommends that measurement of plasma total homocysteine (tHcy) not be paid for with public funds (Professor David Smith, personal communication, 15 June 2018).

However, B vitamin therapy for lowering homocysteine to prevent stroke was...
resurrected by the China Stroke Primary Prevention Trial (CSPPT), in which folic acid reduced ischaemic stroke by 24% in primary prevention. In higher risk groups, the reduction of stroke was greater: among patients with low-density lipoprotein cholesterol >2 mmol/L, the reduction in ischaemic stroke was 36%, and in patients with tHcy >15 and low platelet counts it was 70%. Folic acid did not reduce the risk of haemorrhagic stroke. A recent meta-analysis indicated that B vitamin combinations and folic acid reduced the risk of stroke; the authors recommended folic acid for this purpose in countries where folate fortification does not exist.

Restricting the recommendation to folic acid is problematic, as in countries where folate fortification is in place, the main nutritional determinant of tHcy is deficiency of vitamin B₁₂. It has become apparent in the light of the CSPPT trial that in the early trials of B vitamins for stroke prevention, harm from cyanocobalamin among study participants with renal failure obscured the benefit among participants with good renal function. It is likely that instead of cyanocobalamin, we should be using methylcobalamin or oxocobalamin for stroke prevention.

An important opportunity for prevention of stroke and dementia is metabolic B₁₂ deficiency, which is often missed because most physicians do not realise that a serum total B₁₂ in the ‘normal’ range (~180–670 pmol/L) does not define adequacy of functional vitamin B₁₂. In order to assess B₁₂ function, it is necessary to measure holotranscobalamin, or measure one of the metabolites that become elevated in B₁₂ deficiency: methylmalonic acid (MMA) or tHcy. Although MMA is more specific, homocysteine can substitute for MMA in folate-replete persons (which in countries with folate fortification essentially applies to nearly all patients). The inflection point for serum B₁₂ at which both MMA and tHcy become elevated is 400 pmol/L, so within the normal range of serum B₁₂ there are many patients with metabolic B₁₂ deficiency.

Spence reported in 2009 that at age ≥80, 40% of patients referred for stroke prevention had tHcy ≥14, and in 2006 he reported that metabolic B₁₂ deficiency was present in 10% of patients with stroke/transient ischaemic attack (TIA) aged <50, 13% aged 50–70 and 30% above the age of 70. He routinely requests of referring doctors that serum B₁₂ and plasma lipids be measured before new and follow-up visits, and had noticed that more patients recently had been started on B₁₂ supplements before coming to clinic, after the family physician saw the serum B₁₂ level. It seemed that as a result of reporting such findings to the hundreds of family physicians of some 40,000 patients with stroke/TIA in our region over 40 years, detection and treatment of B₁₂ deficiency in our referral area may have increased.

In this study, we sought to assess the current magnitude of the opportunity for stroke prevention with B vitamins by determining the prevalence of hyperhomocysteinaemia (HHcy) and metabolic B₁₂ deficiency in patients with TIA or minor strokes.

**METHODS**

**Patient population**

Data were obtained from outpatients with TIA or minor stroke referred to the Urgent TIA Clinic at University Hospital in London, Ontario, Canada. Data for 3410 patients referred between 2000 and 2012 were obtained from the database of a study on secular trends in stroke subtypes, data on an additional 1776 patients referred between 2012 and 2017 were obtained from the electronic medical records of the hospital during a 3-month visit by SA, undertaken within a Flexible and Enhanced Learning programme of the University of British Columbia Medical School. Because of the limited time available, data collected on patients referred since 2012 were restricted to age, sex and variables pertinent to the diagnosis of metabolic B₁₂ deficiency and HHcy: serum B₁₂, plasma tHcy and creatinine. Among the 3410 patients referred between 2000 and 2012, stroke subtypes had been assigned using the Subtypes of Ischaemic Stroke Classification System (SPARKLE) classification, which incorporates high carotid plaque burden in the large artery atherosclerosis subtype.

**Blood tests and analyses**

Serum B₁₂, EDTA tHcy and lithium heparin plasma creatinine were measured at the Department of Pathology and Laboratory Medicine of London Health Sciences Centre, London, Ontario, Canada.

Between 2000 and May 2004, serum B₁₂ levels were measured by immunoassay on a Siemens Centaur analyser (reference intervals [RIs]: normal 181–672 pmol/L, indeterminate 155–181 pmol/L, deficient <155 pmol/L). The analysis on this platform continued until January 2014, but in May 2004 the RIs changed to 200–672 pmol/L for normal, 156–200 pmol/L for indeterminate and <156 pmol/L for deficient. Serum B₁₂ was then measured by immunoassay on a Roche e602 with generation I of reagent (RIs: 156–698 pmol/L) until November 2015, and then on Roche e602 and E170 analysers with generation II of reagent (RIs: 145–569 pmol/L) beyond 2017.

Plasma tHcy was measured by high-pressure liquid chromatography (RI: ≤13.5 pmol/L) from 2000 until December 2001. It was then measured by immunoassay on a Siemens Immulite or Immulite 2000 (RI: 5.0–12.0 pmol/L) until May 2011. From May 2011 until February 2014, tHcy was measured by immunoassay on a Siemens Centaur (RI: 3.7–13.9 pmol/L), then using an ELISA from Immuno-Biological Laboratories (RIs: male 4.8–11.8 pmol/L, female 4.3–10.9 pmol/L) until December 2015, and then by immunoassay on an Abbott Architect (RIs: male 5.1–15.4 pmol/L, female 4.4–13.6 pmol/L) beyond 2017.

Plasma creatinine was measured by the Jaffe method on Beckman CX4, CX7 and LX20 analysers from 2000 until November 2008, and then by an enzymatic method on Roche P-Modules beyond 2017. The RIs throughout this entire time were 62–120 µmol/L for male 12 years to adult and 55–100 µmol/L for female 12 years to adult.
Biochemical B₁₂ deficiency was defined as a serum B₁₂ <156 pmol/L. Metabolic B₁₂ deficiency was defined, as recommended by Stabler et al, by a serum B₁₂ <258 pmol/L and tHcy >14 µmol/L. Because tHcy is high in patients with renal failure, a second estimate of metabolic B₁₂ deficiency excluded patients with an estimated glomerular filtration rate (eGFR) <60 mL/min per 1.73 m², computed by the Modification of Diet in Renal Disease (MDRD) equations.

Involvement of patients and the public
There was no involvement of patients other than their data. The public were also not involved.

Statistical methods
Continuous variables were summarised by mean±SD and categorical variables by %. Differences in categorical variables were compared using χ²; post-hoc differences were assessed by computing standardised residual scores for each cell. Continuous variables were assessed by analysis of variance. All tests were performed using SPSS V.25.

RESULTS
Data were available in 4282 patients with values for serum B₁₂ and tHcy. There were 218 patients who had unphysiologically high serum B₁₂ levels from 700 to 2661 pmol/L, indicating that they were probably taking B₁₂ supplements (other possibilities would include laboratory error or errors in data entry): 5.2% of patients before 2009 and 8.1% thereafter (p=0.0001). There were also nine patients whose serum B₁₂ was implausibly low (between 1 and 31 pmol/L, possibly due to laboratory error or errors in data entry). After excluding these patients there remained 4055 patients whose results are presented here.

A Consolidated Standards of Reporting Trials diagram is shown in online supplementary material. Analyses including the patients with serum B₁₂ >700 pmol/L are presented in online supplementary eTable 1 and eTable 2; online supplementary eFigure 1 shows the distribution of serum B₁₂ and tHcy from 2002 to 2017. It is certain from the medication lists in the clinic notes that there were many patients with a serum B₁₂ <700 pmol/L who were also taking B₁₂ supplements, but data on B₁₂ supplementation were not collected, so those patients were included in the analyses. Folate supplementation of the grain supply was implemented in Canada in 1989, and we know from observation in the clinic that very few patients took folate supplements; a substantial proportion (~20%) do take a multivitamin tablet daily.

Biochemical B₁₂ deficiency was present in 8.2% of patients overall; it declined from 10.9% of patients referred before 2009 to 5.4% thereafter (p=0.0001). Metabolic B₁₂ deficiency was present in 10.6% of patients, and HHcy was present in 19.1% of patients. Among patients aged ≥80 years, metabolic B₁₂ deficiency was present in 18.1% and HHcy in 35%. Among the 3410 patients whose stroke subtype was determined, HHcy was present in 18.4% of patients: 23.3% of large artery atherosclerosis, 18.1% of cardioembolic, 16.3% of small vessel disease, 10.8% of other unusual aetiologies and 13.6% of undetermined subtypes (p=0.0001).

Figure 1 shows the distribution of serum B₁₂ and tHcy from 2002 to 2008 versus 2009–2017. The distributions were significantly different by a Kruskal-Wallis test (p=0.0001). Online supplementary data eFigure 1 shows the distribution of serum B₁₂ and tHcy in all the cases, including those with serum B₁₂ >700 pmol/L.

Table 1 shows the characteristics of the patients by metabolic B₁₂ status. Patients with metabolic B₁₂ deficiency were significantly older, male and had smoked more tobacco.

Table 2 shows the prevalence of tHcy ≥14 and of metabolic B₁₂ deficiency by age group.

Both increased significantly with age. At ages 70–80, 23.5% of patients had tHcy ≥14, and at age ≥80 it was 35%.

Figure 2 shows the distribution of tHcy and serum B₁₂ by age.

Open access

quartiles of eGFR. It is clear that patients with impaired renal function have higher tHcy, so metabolic B12 deficiency would not be appropriately defined in them by a tHcy ≥ 14. After excluding patients with eGFR <60, metabolic B12 deficiency was present in 9.2% of patients at ages 70–80, and at age ≥ 80 it was 12.3%. Figure 2 shows the serum B12 and tHcy by age groups.

Table 3 shows the prevalence of tHcy and metabolic B12 deficiency by stroke subtypes. Post-hoc tests for differences are shown in online supplementary material.

Both were significantly more prevalent in patients with large artery disease and cardioembolic stroke, and less prevalent in patients with other rare causes or undetermined causes of stroke. Among the 3410 patients whose stroke subtype was determined, HHcy was present in 18.4% of patients; this differed significantly by stroke subtype: 23.3% of large artery atherosclerosis, 18.1% of cardioembolic, 16.3% of small vessel disease, 10.8% of other unusual aetiologies and 13.6% of undetermined subtypes (p=0.0001) (figure 3).

Table 4 shows the baseline characteristics by stroke subtype.

Figure 4A shows the serum B12 levels by year, and figure 4B shows the number of patients with serum B12 >700 pmol/L by year. It appears that after the 2009 report,12 B12 supplementation became more common in our referral area. Before 2009, serum B12 (mean±SD) was 293.65±135.74 pmol/L; after 2009 it was 356.57±129.18 pmol/L (p=0.001).

**DISCUSSION**

We found that despite evidence of probable increasing B12 supplementation in the community, metabolic B12

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Characteristics of the study population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Metabolic B12 deficiency</strong></td>
<td><strong>No, n=3626</strong></td>
</tr>
<tr>
<td><strong>Continuous variables, mean±SD</strong></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>64.41±14.46</td>
</tr>
<tr>
<td>Systolic pressure</td>
<td>143.57±21.87</td>
</tr>
<tr>
<td>Diastolic pressure</td>
<td>81.75±12.69</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.81±1.19</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>1.84±1.26</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>1.34±0.43</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>2.67±1.02</td>
</tr>
<tr>
<td>Smoking (pack-years)</td>
<td>15.64±20.98</td>
</tr>
<tr>
<td>Serum B12 (pmol/L)</td>
<td>319.05±128.62</td>
</tr>
<tr>
<td>tHcy (µmol/L)</td>
<td>10.14±4.36</td>
</tr>
<tr>
<td>Plasma creatinine (µmol/L)</td>
<td>84.10±38.85</td>
</tr>
<tr>
<td>eGFR</td>
<td>76.48±21.33</td>
</tr>
<tr>
<td><strong>Categorical variables, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1831 (50.5)</td>
</tr>
</tbody>
</table>

ANOVA, analysis of variance; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; tHcy, plasma total homocysteine.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Age groups, hyperhomocysteinaemia and B12 deficiency, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age group</strong></td>
<td>&lt;50</td>
</tr>
<tr>
<td>tHcy &gt;14*</td>
<td>51 (8.0)†</td>
</tr>
<tr>
<td>Biochemical B12 deficiency‡</td>
<td>57 (8.2)</td>
</tr>
<tr>
<td>Metabolic B12 deficiency§</td>
<td>27 (3.9)†</td>
</tr>
<tr>
<td>Metabolic B12 deficiency ²¶</td>
<td>14 (3.4)†</td>
</tr>
</tbody>
</table>

Age groups are approximately quintiles of the study population.
* tHcy, plasma total homocysteine.
† Statistically significant difference from other categories in post-hoc testing.
‡ Serum B12 <156 pmol/L.
§ Serum B12 <258 and pmol/L and tHcy >14 µmol/L.
¶ Excluding patients with eGFR <60.
deficiency and HHcy remain common among patients referred for TIA or minor stroke.

The shift to higher serum $B_{12}$ levels over time is unlikely to be due to reasons other than $B_{12}$ supplementation. The high end of the reference range of 698 pmol/L represents the 95th percentile for all patients, including those who received supplements; plasma levels above 700 pmol/L are unlikely to be physiological, and are therefore probably due to supplementation. Figure 4B shows that the percentage of patients with a serum $B_{12}$ >700 pmol/L increased after 2014 from ~5% of patients to 17.5%; this is very unlikely to be due to anything other than supplements. As the principal dietary source of $B_{12}$ is meat, changes to a healthier lifestyle would not account for increases in serum $B_{12}$. It appears therefore that an increase in awareness and treatment of $B_{12}$ deficiency since 2009 in our referral area has resulted in a decline in recent years in the prevalence of metabolic $B_{12}$ deficiency and HHcy among patients referred with stroke or TIA. This is supported by the decline in HHcy since the 2009 report from this clinic population (from 40% of patients aged >80 to 35%$^{12}$) and the decline in the prevalence of HHcy since the 2006 report (from 30% of patients aged ≥71 to 15.9% aged ≥80).$^{13}$ Nevertheless, $B_{12}$ deficiency and HHcy remain common in this patient population.

Including some patients who probably received $B_{12}$ supplementation in the analyses probably resulted in an underestimate of the prevalence of metabolic $B_{12}$ deficiency and HHcy that would be observed among patients with stroke/TIA, absent supplementation.

HHcy and low eGFR were more common in patients with large artery disease, who were older than patients with other stroke subtypes. Plasma tHcy has previously been reported to be associated with carotid total plaque area.$^{18,19}$ Renal function declines with age, and tHcy levels increase with age.

We found that despite probable increases in $B_{12}$ supplementation in our community, HHcy and metabolic deficiency are still common in patients with stroke, particularly in older patients. These findings are important on several counts. As discussed above, $B$ vitamins to lower tHcy reduce the risk of stroke. Besides increasing the risk of stroke by raising tHcy, $B_{12}$ deficiency also causes neuropathy, myelopathy and dementia. Cognitive decline is common in patients with stroke, and treating $B_{12}$ deficiency and HHcy can prevent dementia.$^{20-22}$ In a recent meta-analysis, patients with higher blood levels of $B_{12}$, $B_6$ and folate had a reduced risk of developing atrial fibrillation, a known risk factor for cardioembolic strokes.$^{23}$ Falls in the elderly, an important cause of disability, are probably also increased by loss of position sense with $B_{12}$ deficiency.

![Figure 2](https://example.com/figure2.png) **Figure 2** Plasma total homocysteine (tHcy) and serum $B_{12}$ by quartiles of estimated glomerular filtration rate (eGFR). (A) tHcy was clearly elevated with impaired renal function. (B) Serum $B_{12}$ was not significantly affected by renal impairment.

| Table 3 Stroke subtypes, hyperhomocysteinaemia and metabolic $B_{12}$ deficiency, n (%) |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Stroke subtypes | Large artery disease | Cardioembolic | Small vessel disease | Other rare or unusual aetiologies | Undetermined | P value |
| tHcy >14* | 256 (23.3)† | 238 (18.1) | 57 (16.3) | 21 (10.8)† | 72 (13.6)† | 0.0001 |
| Biochemical $B_{12}$ deficiency‡ | 111 (10.1) | 104 (7.9) | 28 (8.5) | 23 (11.3) | 45 (8.5) | 0.27 |
| Metabolic $B_{12}$ deficiency§ | 139 (12.7)† | 121 (9.2) | 31 (8.8) | 11 (5.4)† | 44 (8.1) | 0.002 |
| Metabolic $B_{12}$ deficiency 2¶ | 49 (10.9) | 48 (6.8) | 11 (6.2) | 4 (4.3) | 15 (5.2)† | 0.001 |

Stroke subtypes were as defined among 3466 of the cases in a previous study.$^{14}$

* tHcy, plasma total homocysteine µmol/L.
† Statistically significant difference from other categories in post-hoc testing.
‡ Serum $B_{12}$ <156 pmol/L.
§ Serum $B_{12}$ <258 and pmol/L and tHcy >14 µmol/L.
¶ Excluding patients with estimated glomerular filtration rate <60.

It also seems likely that patients in other regions and patients with more severe strokes may have a greater prevalence of both these conditions. In the Newcastle 85+ study, the lowest quartile of plasma B12 was <170 pmol/L, with tHcy 19.9 (95% CI 16.3 to 24.6); that is, 25% of UK patients whose age in 2006 was 85 years had metabolic B12 deficiency. B12 deficiency is very common in India, in part because of a high prevalence of vegetarianism. Even in adolescents, B12 deficiency was reported in 32% of study participants in the Haryana region.24 In Pakistan 58.3% of patients with ischaemic stroke were reported to have HHcy defined as tHcy >15 µmol/L 25; in China the prevalence of tHcy >30 µmol/L among patients with hypertension was 16.7%.26 It would therefore be important to assess the prevalence of HHcy and metabolic B12 deficiency in other stroke populations. It would also be very important to assess serum B12 and tHcy in patients with cognitive impairment.20 27 28

Table 4  Baseline characteristics by stroke subtype for cases with serum B12 <700 pmol/L

<table>
<thead>
<tr>
<th>Continuous variables, mean±SD (ANOVA)</th>
<th>Large artery</th>
<th>Cardioembolic</th>
<th>Small vessel</th>
<th>Other unusual</th>
<th>Undetermined</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>70.08±10.93</td>
<td>62.23±15.96</td>
<td>65.94±13.11</td>
<td>53.32±14.39</td>
<td>64.02±14.84</td>
<td>0.0001</td>
</tr>
<tr>
<td>Systolic pressure (mm Hg)</td>
<td>143.82±20.81</td>
<td>135.40±19.41</td>
<td>157.52±24.37</td>
<td>140.67±20.69</td>
<td>142.70±21.13</td>
<td>0.0001</td>
</tr>
<tr>
<td>Diastolic pressure (mm Hg)</td>
<td>80.26±12.44</td>
<td>79.16±12.34</td>
<td>86.48±14.54</td>
<td>81.77±12.74</td>
<td>81.15±11.16</td>
<td>0.001</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.71±1.21</td>
<td>4.74±1.12</td>
<td>4.93±1.20</td>
<td>5.04±1.20</td>
<td>4.96±1.18</td>
<td>0.003</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>1.94±1.30</td>
<td>1.69±1.16</td>
<td>2.03±1.78</td>
<td>1.87±0.94</td>
<td>1.85±1.14</td>
<td>0.001</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>1.28±0.40</td>
<td>1.35±0.43</td>
<td>1.34±0.44</td>
<td>1.29±0.39</td>
<td>1.37±0.42</td>
<td>0.009</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>2.60±1.04</td>
<td>2.64±0.95</td>
<td>2.71±0.98</td>
<td>2.89±1.07</td>
<td>2.79±1.01</td>
<td>0.019</td>
</tr>
<tr>
<td>Smoking (pack-years)</td>
<td>25.29±23.34</td>
<td>17.62±19.89</td>
<td>21.03±22.16</td>
<td>11.06±16.28</td>
<td>16.16±17.07</td>
<td>0.0001</td>
</tr>
<tr>
<td>Serum B12 (pmol/L)</td>
<td>298.44±129.85</td>
<td>300.47±125.20</td>
<td>294.10±122.67</td>
<td>291.95±122.63</td>
<td>302.71±132.71</td>
<td>0.785</td>
</tr>
<tr>
<td>tHcy (µmol/L)</td>
<td>11.96±5.34</td>
<td>10.91±5.25</td>
<td>11.04±4.71</td>
<td>9.20±4.14</td>
<td>10.28±4.91</td>
<td>0.0001</td>
</tr>
<tr>
<td>Plasma creatinine (µ mol/L)</td>
<td>94.29±32.21</td>
<td>82.72±34.31</td>
<td>88.00±52.04</td>
<td>79.12±20.25</td>
<td>83.92±41.67</td>
<td>0.0001</td>
</tr>
<tr>
<td>eGFR</td>
<td>68.04±20.77</td>
<td>76.78±21.28</td>
<td>73.70±21.67</td>
<td>80.05±22.07</td>
<td>76.84±23.90</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

Categorical value, n (%)  χ²

| Male | 668 (62.2)* | 571 (44.3)* | 158 (48.0) | 77 (38.1)* | 238 (46.2)* | 0.0001 |

Post-hoc testing for continuous variables is shown in online supplementary material.

*Statistically significant difference from other categories in post-hoc testing.

ANOVA, analysis of variance; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; tHcy, plasma total homocysteine.

CONCLUSION

Despite a probable increase in B12 supplementation in our referral area in recent years, metabolic B12 deficiency and...
HHcy remain common in patients with TIA or stroke. As these conditions have serious consequences and are easily treated, serum B12 and tHcy should be measured in all patients with ischaemic stroke.

**Author affiliations**

1. University of British Columbia Medical School, Vancouver, British Columbia, Canada
2. Department of Neurology and Biostatistics, Western University, London, Ontario, Canada
3. University of Victoria, Victoria, British Columbia, Canada
4. Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada
5. Dementia and Heart Disease Lab, Western University, London, Ontario, Canada
6. Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, London, Ontario, Canada
7. Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada
8. Division of Clinical Pharmacology, Department of Medicine, Western University, London, Ontario, Canada
9. University Hospital, London, Ontario, Canada

**Contributors**

JDS conceived of the study. CB collected the data on patients referred before 2012 and assigned the stroke subtypes under the supervision of DGH and JDS, and SA collected the data from the patients referred since 2012, during a 3-month elective rotation. Statistical analyses were performed by SA and JDS, and ACR supervised the measurements of total homocysteine and B12 and provided information on the methods. SA wrote the first draft; all authors contributed to revisions of the manuscript. JDS wrote revisions based on comments from the other authors and completed the final draft of the manuscript. The other authors (DGH, LAS, AK, JM, MRA and VH) also cared for the patients, ordered the laboratory tests and obtained approval for the study from the University Ethics Committee. The corresponding author accepts full responsibility for the work and/ or the conduct of the study, had access to the data, and controlled the decision to publish, that all listed authors meet the authorship criteria and that no others meeting the criteria have been omitted.

**Funding**

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Disclaimer**

JDS affirms that the manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data sharing statement**

Data may be shared if permission is first obtained from the World Health Organization for submission to several peer-reviewed journals.

**Disclosure**

The authors have no conflicts of interest to disclose.

**Funding**

JDS is supported by a grant from the Canadian Institute for Health Research (MOP-138301). The study was supported by the Canadian Institutes of Health Research (CIHR) Office of the Director of Research Ethics (grant number 334772) and the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (grant number UL1TR001425).

**Conflicts of interest**

All authors declare no conflicts of interest.

**Competing interests**

All authors declare no competing interests.

**Acknowledgements**

JDS is grateful to the study participants and the study nurses for their contributions to this study.

**Competing interests**

All authors declare no competing interests.

**Ethics approval**

The study was approved by the institutional review board of the University of Western Ontario (ethics approval number 111558)

**Patient consent for publication**

Not required.

**References**


**Figure 4**

Serum B12 by year of referral and per cent of patients with serum B12 >700 pmol/L at the time of referral. (A) Serum B12 levels increased among patients referred to our clinic after the 2009 report of a high prevalence of hyperhomocysteinaemia in our patients. Before 2009 the mean serum B12 (SD) was 326.62 (214.68); thereafter it was 374.90 (234.29) (p=0.0001). (B) The per cent of patients with serum B12 >700 pmol/L increased markedly in recent years, indicating probable B12 supplementation.